Clover Health Investments Corp expected to post a loss of 5 cents a share - Earnings Preview

Clover Health Investments

02/08/2024 23:35

* Clover Health Investments Corp  CLOV.OQ   CLOV.O  is
expected
to show a fall in quarterly revenue when it reports  results on
August 5 for the period ending June 30 2024
    * The Franklin Tennessee-based  company is expected to
report a
34.0% decrease in revenue to $338.764 million from $513.63
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Clover Health
Investments Corp
is for a loss of 5 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Clover
Health
Investments Corp is $1.38​, below​ its last closing price
of $1.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.06       -0.07      -0.04     Beat    44.7
 Dec. 31 2024  -0.10       -0.14      -0.14     Met     -0.5
 Jan. 1 0001   -0.10       -0.11      -0.09     Beat    14.8​
 Jun. 30 2023  -0.15       -0.15      -0.06     Beat    60.1
 ​​Mar.        -0.17       -0.18      -0.15     Beat    14.7
 31 2023                                                
 Dec. 31 2022  -0.23       -0.26      -0.17     Beat    31.4​
 Sep. 30 2022  -0.25       -0.24      -0.16     Beat    33.1
 Jun. 30 2022  -0.21       -0.21      -0.22     Missed  -6.7
 This summary was machine generated August 2 at 22:35 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)